Kaken Pharmaceutical Co., Ltd.
4521.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.29 | -1.27 | 0.04 | -0.14 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 53.04 | 88.55 | -26.36 | 17.10 |
| Quality | ||||
| ROIC | 0.09% | 0.01% | -2.26% | 2.50% |
| Gross Margin | 57.14% | 52.32% | 50.26% | 61.30% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 4.28% | 9.07% | 8.81% | 8.10% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -22.55 | -48.68 | 10.62 | -9.06 |
| Interest Coverage | 17.18 | 1.40 | -517.33 | 834.43 |
| Efficiency | ||||
| Inventory Turnover | 0.48 | 0.49 | 0.47 | 0.54 |
| Cash Conversion Cycle | 221.99 | 224.85 | 212.89 | 187.59 |